Rani Therapeutics' Oral GLP-1/GLP-2 Capsule RT-114 Achieves Bioavailability Exceeding 150% of Subcutaneous Dose in Phase 1a Trial
Key Insights
Oral RT-114 delivered via RaniPill Capsule achieved systemic exposure greater than 150% relative to a matched 12 mg subcutaneous dose of PG-102 in a 30-person Phase 1a study.
Elimination half-life was nearly identical between oral (5.6 days) and subcutaneous (5.3 days) arms, suggesting intact peptide delivery into systemic circulation.
No adverse events were attributed to the RaniPill Capsule device; treatment-related events were mild, transient, and consistent with the GLP-1 (search)/GLP-2 (search) agonist class.
Oral RT-114, a RaniPill Capsule delivering the GLP-1 (search)/GLP-2 (search) dual agonist PG-102, achieved systemic exposure greater than 150% relative to a matched 12 mg subcutaneous dose in an ongoing Phase 1a study, Rani Therapeutics Holdings, Inc. reported on July 15, 2026. The result marks a striking departure from the bioavailability constraints that have long defined oral biologic delivery, where even the most advanced oral peptide formulations typically yield only a fraction of injectable exposure.
"The safety and bioavailability findings reported today exceeded our expectations and represent an important milestone for the RaniPill platform," said Talat Imran, Chief Executive Officer of Rani. "At a time when many oral biologic delivery technologies continue to produce only a small fraction of subcutaneous exposure, these data reinforce the unique potential of the RaniPill platform."
Pharmacokinetic Profile and Safety
The single-dose, open-label Phase 1a portion of the study enrolled 30 healthy volunteers randomized to receive an identical 12 mg dose of PG-102, delivered either orally via RT-114 or by subcutaneous injection. Beyond the headline bioavailability figure, the pharmacokinetic data revealed a near-identical elimination half-life between arms: 5.6 days for oral RT-114 versus 5.3 days for subcutaneous PG-102. This concordance suggests the RaniPill capsule is delivering intact peptide into systemic circulation rather than a degraded fragment.
No serious adverse events were reported in either arm, and no adverse events were attributed to the RaniPill Capsule itself. Treatment-related adverse events—including nausea, vomiting, and diarrhea—were mild, transient, and consistent with the known profile of GLP-1 (search)/GLP-2 (search) dual agonists. The clean device safety record carries particular significance given that any novel delivery mechanism introduces its own risk surface; Rani's capsule, which uses a small needle to inject drug directly into the intestinal wall, has now cleared that bar in this indication.
Study Expansion and Next Steps
Because oral exposure exceeded subcutaneous levels by more than 50%, dose selection for the next phase requires re-evaluation rather than simple extrapolation. Rani is expanding the Phase 1a study with an additional 15-person cohort in which participants will each receive two separate 12 mg doses of PG-102 via the RaniPill (24 mg total administered dose), specifically to map the dose-concentration relationship before committing to a Phase 1b design.
"The magnitude of exposure achieved with oral RT-114 relative to subcutaneous administration may give us greater flexibility to explore a higher range of serum concentrations using fewer and more practical oral doses than we had previously anticipated," Imran added. "We are therefore expanding the Phase 1a study with an additional cohort to help inform dose selection for the repeat-dose Phase 1b study."
The planned Phase 1b study will assess safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity (search). That study is expected to begin in 2026, with data anticipated in 2027.
Collaboration Structure
RT-114 is being developed under a Collaboration Agreement between Rani and ProGen Co., Ltd., entered into in June 2024. Under the agreement, development costs and future operating profits and losses from commercialization will be equally shared. Rani leads development through Phase 1, and after initiation of the first Phase 2 clinical trial, Rani will lead development and commercialization in the United States, Canada, Europe (including the United Kingdom), and Australia, while ProGen will lead in all other countries.
The Defining Question Ahead
Bioavailability above the subcutaneous comparator is a necessary condition for efficacy, not a guarantee of it. The result that will define RT-114's trajectory is not the pharmacokinetic data in healthy volunteers but the pharmacodynamic weight-loss signal in the Phase 1b obesity (search) cohort. The eight-week body weight data from that study will determine whether RaniPill's exposure advantage translates into clinically meaningful weight reduction at practical oral doses, or whether peptide delivery and receptor pharmacology diverge in ways the Phase 1a PK data cannot anticipate.